Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Erlotinib and everolimus may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab
and everolimus may also block blood flow to the tumor. Giving everolimus and erlotinib
together with bevacizumab may kill more tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects and best dose of
erlotinib and everolimus when given together with bevacizumab in treating patients with
advanced solid tumors.